Session: SAT 134-163-GnRH & Gonadotroph Biology & Signaling
Bench to Bedside
Poster Board SAT-152
Objectives: To evaluate the prevalence of biochemical hypogonadism in a population of HIV-1-infected patients on antiretroviral combined therapy (cART) and to compare the prevalence of hypogonadism, according to TT or FT or TT and/or FT.
Patients and Methods: We evaluated hormonal parameters (SHBG, TT, FT, FSH and LH) in 155 HIV-1-infected patients on cART.
Results: In all patients: 19.3% (30/155) had low TT and/or FT; 8.39% (13/155) low TT and 14.84% (23/155) low FT. Of the patients with biochemical hypogonadism, 66.6% (20/30) were normagonodotropic, 6.67% (2/30) hypogonadotropic and 26.67% (8/30) hypergonadotrophic. In all patients, 28.38% (44/155) had increased SHBG. Those with increased SHBG: 1) 2.27% (1/44) had low TT, 2) 20.45% (9/44) had lower FT, 3) 47.72% (21/44) had increased TT; 4) 2.27% (1/44) had lower FT and increased TT. Of the patients with biochemical hypogonadism (30/155), 26.67% (8/30) had increased SHBG. All of these 8 patients had low FT, 12.5% (1/8) had low TT and 12.5% (1/8) had increased TT. Of the patients with low FT, 26.1% (6/23) had low TT; 4.34% (1/23) had increased TT and 69.6% (16/23) had normal TT.
Conclusion: Our data suggest that the exclusive use of TT can underdiagnose hypogonadism.
Nothing to Disclose: PF, EL, MJM, RS, SX, AS, DC
*Please take note of The Endocrine Society's News Embargo Policy at http://www.endo-society.org/endo2013/media.cfm
See more of: Abstracts - Orals, Featured Poster Presentations, and Posters